CytoSorbents appoints Thomas Shannon as VP of Marketing for North America ahead of DrugSorb-ATR launch

Cytosorbents Corp

Thomas Shannon appointed VP of Marketing, North America; will lead strategy for DrugSorb-ATR in U.S. and Canada.
Shannon has 25+ years commercializing cardiovascular and critical care devices at Fresenius, Getinge, Medtronic.
DrugSorb-ATR is an FDA Breakthrough device for perioperative bleeding in CABG patients on Brilinta; regulatory decisions expected in 2025.
CEO Dr. Phillip Chan highlights Shannon's expertise as 'invaluable' for commercialization as company awaits FDA/Health Canada approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.